Published in AIDS Weekly, April 10th, 2000
Achillion, a privately held biopharmaceutical company located in New Haven, recently completed a Series B financing and is commencing operations to develop and commercialize innovative antiviral therapies. Under the terms of the license agreement, Achillion will fund the development of (beta)-L-Fd4C, which it intends to develop as one of its key product candidates.
Preclinical studies of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.